Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Health Canada has granted full approval to dostarlimab monotherapy for patients with recurrent or advanced dMMR/MSI-H endometrial cancer.

Dostarlimab Wins Full Approval in Canada for dMMR/MSI-H Endometrial Cancer

Donor fecal microbiota transplants increased the activity of immunotherapy in patients with GI cancers.

Fecal Microbiota Transplants May Enhance Immunotherapy Efficacy in GI Cancers

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Bintrafusp alfa elicited responses in patients with recurrent/metastatic cervical cancer, warranting further exploration of TGF-β-targeted therapies.

Bintrafusp Alfa Induces Responses in Post-Platinum Metastatic Cervical Cancer 

The FDA has accepted the resubmission of a BLA for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.

FDA Accepts Resubmission of BLA for Cosibelimab in Locally Advanced or Metastatic CSCC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Sidney Kimmel Cancer Center

Videos

Sidney Kimmel Cancer Center at Thomas Jefferson University Stands Out

Leonard G. Gomella, MD, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.  



Dr. Gomella on Using Novel Biomarkers to Inform Biopsy Vs Observation in Prostate Cancer 

Evan J. Lipson, MD, discusses the role of circulating tumor DNA ​testing in melanoma. 

Dr. Lipson on the Role of ctDNA Testing in Melanoma

Evan J. Lipson, MD, discusses the role of ctDNA in the neoadjuvant, adjuvant, and metastatic settings in the realm of melanoma, remaining questions with this marker, and future directions to optimize its use in this disease.

Lipson Sheds Light on the Evolving Role of ctDNA in the Realm of Melanoma 

Julie R. Brahmer, MD, MSc, discusses how data from the CheckMate 227 trial may affect the treatment landscape for NSCLC and notes the quality-of-life outcomes reported with nivolumab and ipilimumab.

Brahmer Discusses Influence of 5-Year Nivolumab and Ipilimumab OS Data in Metastatic NSCLC

Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.

Dr. Seedor on Treatment Sequencing in Metastatic Melanoma

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.


Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer

Sidney Kimmel Cancer Center at Thomas Jefferson University Stands Out

Latest Conference Coverage